Long-acting prescriptions and therapy for HIV-1 from market launch to the present in Germany (May 2021 to December 2023)
BackgroundIn Europe, the combination of cabotegravir (CAB) with rilpivirine (RPV) has been approved as a dual injection long-acting (LA) therapy for the treatment of human immunodeficiency virus type 1 (HIV-1) infections in adults since December 2020. Studies have shown that between 36 and 61% of pe...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Kniha |
| Vydáno: |
Frontiers Media S.A.,
2024-05-01T00:00:00Z.
|
| Témata: | |
| On-line přístup: | Connect to this object online. |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Jednotka 1 | Dostupné |